Is Parasma profitable in 2026?

No. Parasma is a pre-revenue, pre-product Y Combinator S26 company with a team of one as of July 2026, per YC's own jobs page. No revenue, customers, or named-logo data have been reported by any source as of that date.

Could AI replace Parasma's work?

Parasma's core task, encoding and decoding signals between digital tasks and living neuron electrode arrays, is ML-adjacent work that rival FinalSpark already partially automates by pairing an LLM with its Neuroplatform, reported July 2026, narrowing any labor advantage Parasma's small team might have.

Parasma is privately held and backed by Y Combinator as part of its Summer 2026 (S26) batch. No dollar amount for YC or other funding has been publicly disclosed, and the company is run by a team of one as of July 2026.

Who is Parasma's biggest competitor?

Cortical Labs, which sells the CL1 biological computer (about 800,000 neurons per chip, roughly $35,000 per unit, 115 units shipped in 2025) and whose own cloud platform and API were used to run Parasma's widely covered neurons-playing-Doom demo in March 2026.

Did Parasma build its own brain-cell computer hardware?

No confirmed independent hardware has been reported. Parasma's flagship neurons-playing-Doom demo, covered by Futurism on March 1, 2026, was executed using Cortical Labs' cloud platform and API rather than any hardware built or owned by Parasma.

Has Parasma raised a seed funding round?

No confirmed funding amount has been disclosed as of July 2026 beyond being part of Y Combinator's S26 batch. Rival The Biological Computing Co. raised a disclosed $25 million seed round in February 2026, a scale not reported for Parasma.

YC Summer 2026 · United States

Parasma

One-person startup writing training algorithms for cultured human neurons it doesn't own.

Little protection left

Assessed 27 July 2026 · Evidence as of 27 July 2026

Not much stands between this business and its pressures.

On the recordSince 27 July 2026 · Checkable from late 2026 · Every call on the record Checkpoint: Parasma's open Founding Scientist role gets filled (or stays empty)

The call

Parasma is a single founder writing training code for neurons it rents from Cortical Labs, while the company that owns the neurons builds that same code itself.

Parasma writes software and algorithms for biological computing devices, but it does not own or build the actual brain chips and neurons. The real problem is that companies like Cortical Labs and FinalSpark already own the hardware and are writing their own software too, so they can do everything Parasma does plus keep all the profit. Right now, Parasma's only famous demo was actually run on Cortical Labs' equipment, not Parasma's own technology. The one thing that could change this is if Parasma hires a senior scientist who brings their own biotech know-how or exclusive partnerships, which would let Parasma move from renting hardware to having something truly its own. Without that, the hardware makers will likely just do the software themselves and leave no room for a middleman.

Why

AI pressure: General-purpose coding AI agents (e.g. GPT-5-class copilots). If neuron-training code is mostly software, AI coding agents could let anyone replicate Parasma's algorithms in-house. Could AI do the core job? Yes, likely.

Bigger players: Cortical Labs. Cortical Labs owns the CL1 hardware Parasma's own demo ran on and already ships its own SDK, cutting out the need for Parasma's layer. Could a giant copy it? Yes, easily.

What protects it. A working Doom-on-neurons demo and a YC S26 slot, but no owned substrate, patent, or exclusive deal with any hardware maker.

What would change this call

Parasma fills its open Founding Scientist role within 12 months. Shows whether Parasma gains wet-lab substrate expertise or stays a pure software layer.
Parasma announces a shipped product or paying design partner by early 2027. Would confirm Parasma has moved past pre-product, one-person status.
Cortical Labs or FinalSpark announces its own algorithms/software layer for customers. Would show hardware owners closing the gap Parasma hoped to fill.

Key numbers

Cortical Labs shipped 115 CL1 units (2025)
TBC raised $25M seed round (Feb 2026)
FinalSpark Neuroplatform rents from $500/month (2023)

Named risks

Single-founder, pre-product company with no owned hardware, patents, or customers as of July 2026. Severity: high
Flagship demo depended entirely on a direct competitor's (Cortical Labs) hardware and API. Severity: high
Better-funded rivals (TBC's $25M seed, Cortical Labs shipping units) could absorb the niche before Parasma ships. Severity: high
Unresolved regulatory and ethical scrutiny of human-neuron biocomputing could affect the whole category. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Cortical Labs	losing to	Parasma's own headline Doom demo ran on Cortical Labs' hardware and API, March 2026
FinalSpark	losing to	FinalSpark has run a live rentable Neuroplatform since 2023, plus LLM autonomy added by July 2026
The Biological Computing Co. (TBC)	losing to	TBC raised a disclosed $25M seed round in Feb 2026; Parasma has no disclosed funding
Koniku	contesting	Koniku has commercial neuron-silicon sensing contracts dating to 2017, a different niche than Parasma's compute focus

Questions people ask

Is Parasma profitable in 2026?: No. Parasma is a pre-revenue, pre-product Y Combinator S26 company with a team of one as of July 2026, per YC's own jobs page. No revenue, customers, or named-logo data have been reported by any source as of that date.
Could AI replace Parasma's work?: Parasma's core task, encoding and decoding signals between digital tasks and living neuron electrode arrays, is ML-adjacent work that rival FinalSpark already partially automates by pairing an LLM with its Neuroplatform, reported July 2026, narrowing any labor advantage Parasma's small team might have.
Who owns Parasma?: Parasma is privately held and backed by Y Combinator as part of its Summer 2026 (S26) batch. No dollar amount for YC or other funding has been publicly disclosed, and the company is run by a team of one as of July 2026.
Who is Parasma's biggest competitor?: Cortical Labs, which sells the CL1 biological computer (about 800,000 neurons per chip, roughly $35,000 per unit, 115 units shipped in 2025) and whose own cloud platform and API were used to run Parasma's widely covered neurons-playing-Doom demo in March 2026.
Did Parasma build its own brain-cell computer hardware?: No confirmed independent hardware has been reported. Parasma's flagship neurons-playing-Doom demo, covered by Futurism on March 1, 2026, was executed using Cortical Labs' cloud platform and API rather than any hardware built or owned by Parasma.
Has Parasma raised a seed funding round?: No confirmed funding amount has been disclosed as of July 2026 beyond being part of Y Combinator's S26 batch. Rival The Biological Computing Co. raised a disclosed $25 million seed round in February 2026, a scale not reported for Parasma.

Timeline

2026-07-20FinalSpark reported connecting its Neuroplatform to an LLM for autonomous experiments
2026-07-03YC jobs page lists Parasma team size as 1, actively hiring Founding Scientist role
2026-03-03Decrypt corroborates human neurons playing Doom on Cortical Labs' platform
2026-03-01Futurism reports cultured human neurons taught to play Doom via Cortical Labs' API in about one week
2026-02-28TechSpot reports Cortical Labs CL1 uses ~800,000 neurons, priced near $35,000 per unit
2026-02-12Rival The Biological Computing Co. (TBC) secures $25 million seed round led by Primary
2026-02-11Yahoo Finance reports TBC founded by two neurosurgeons betting on neuron compute
2025-12-04Techxplore flags emerging ethical and regulatory scrutiny of human-neuron biocomputing
2024-08-14Scientific American reports FinalSpark's Neuroplatform rentable since 2023 at about $500 per month

Revision history

27 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Cerenovus Belvedir Hoplite